Aarti Pharmalabs (NSE:AARTIPHARM) Asset Turnover: 0.17 (As of Mar. 2026)


NSE:AARTIPHARM Aarti Pharmalabs Ltd NSE:AARTIPHARM
56 GF Score
Price ₹690.70
GF Value ₹636.14
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Aarti Pharmalabs Asset Turnover?

Aarti Pharmalabs NSE:AARTIPHARM -2.73% 56 Asset Turnover is 0.17 as of Mar. 2026. GuruFocus rates NSE:AARTIPHARM with a GF Score™ of 56/100 and a GF Value™ of ₹636.14 (Fairly Valued). The stock has 3 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Aarti Pharmalabs's Revenue for the three months ended in Mar. 2026 was ₹5,826 Mil. Aarti Pharmalabs's Total Assets for the quarter that ended in Mar. 2026 was ₹34,817 Mil. Therefore, Aarti Pharmalabs's Asset Turnover for the quarter that ended in Mar. 2026 was 0.17.

Asset Turnover is linked to ROE % through Du Pont Formula. Aarti Pharmalabs's annualized ROE % for the quarter that ended in Mar. 2026 was 11.51%. It is also linked to ROA % through Du Pont Formula. Aarti Pharmalabs's annualized ROA % for the quarter that ended in Mar. 2026 was 7.02%.


Aarti Pharmalabs  (NSE:AARTIPHARM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Aarti Pharmalabs's annulized ROE % for the quarter that ended in Mar. 2026 is

ROE %**(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=2444.964/21246.047
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(2444.964 / 23305.76)*(23305.76 / 34817.059)*(34817.059/ 21246.047)
=Net Margin %*Asset Turnover*Equity Multiplier
=10.49 %*0.6694*1.6388
=ROA %*Equity Multiplier
=7.02 %*1.6388
=11.51 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Aarti Pharmalabs's annulized ROA % for the quarter that ended in Mar. 2026 is

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=2444.964/34817.059
=(Net Income / Revenue)*(Revenue / Total Assets)
=(2444.964 / 23305.76)*(23305.76 / 34817.059)
=Net Margin %*Asset Turnover
=10.49 %*0.6694
=7.02 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Aarti Pharmalabs Asset Turnover Related Terms


Aarti Pharmalabs Asset Turnover Historical Data

* Premium members only.

The historical data trend for Aarti Pharmalabs's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Pharmalabs Asset Turnover Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Asset Turnover
Get a 7-Day Free Trial 1.17 0.90 0.75 0.77 0.57

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.13 0.13 0.13 0.17

NSE:AARTIPHARM vs ZTS, UTHR: Asset Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Pharmalabs Asset Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Aarti Pharmalabs's Asset Turnover falls into.


NSE:AARTIPHARM
56GF Score
Aarti Pharmalabs Ltd NSE:AARTIPHARM
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Pharmalabs Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Aarti Pharmalabs's Asset Turnover for the fiscal year that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2026 )/( (Total Assets (A: Mar. 2025 )+Total Assets (A: Mar. 2026 ))/ count )
=18194.425/( (29064.051+34817.059)/ 2 )
=18194.425/31940.555
=0.57

Aarti Pharmalabs's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=5826.44/( (0+34817.059)/ 1 )
=5826.44/34817.059
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.17 mean?
Aarti Pharmalabs (NSE:AARTIPHARM) has a Asset Turnover of 0.17 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Aarti Pharmalabs and its competitors.
Is Aarti Pharmalabs' Asset Turnover too high?
Aarti Pharmalabs' current Asset Turnover is 0.17. Overall, Aarti Pharmalabs has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' Asset Turnover compare to ZTS and UTHR?
Aarti Pharmalabs' Asset Turnover of 0.17 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Drug Manufacturers company?
A good Asset Turnover depends on the Drug Manufacturers industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Aarti Pharmalabs and its competitors. Aarti Pharmalabs's current Asset Turnover is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹636.14, compared to a current price of ₹690.70 — trading 8.6% above its estimated fair value. The current Asset Turnover is 0.17. Aarti Pharmalabs' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current Asset Turnover is 0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued. The current stock price of ₹690.70 is trading 8.6% above its estimated GF Value™ of ₹636.14. GuruFocus considers Aarti Pharmalabs to be Fairly Valued.

Key valuation signals for NSE:AARTIPHARM:

  • Asset Turnover: 0.17
  • GF Value™: ₹636.14 vs. price of ₹690.70 (8.6% above fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aarti Pharmalabs Business Description

Other Exchanges 543748:India
Address Mulund Goregaon Link Road, 204, 2nd Floor, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
56GF Score

Get the complete analysis for NSE:AARTIPHARM

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹690.70
Price
₹636.14
GF Value